FDA Approval of Tislelizumab
Rahul Gosain, MD, MBA; Rohit Gosain, MD; and Anwaar Saeed, MD, evaluate the RATIONALE-305 and RATIONALE-306 trials, investigating tislelizumab and examining the trials’ key end points, including overall survival, progression-free survival, and safety outcomes.
EP. 2: Overall Survival Benefit Update From RATIONALE-305
March 13th 2025Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.
Watch
EP. 3: RATIONALE-305: Exploring Adverse Event Profile
March 13th 2025Panelists discuss how the RATIONALE-305 trial revealed a manageable adverse event profile for tislelizumab plus chemotherapy despite increased rates of neutropenia and anemia compared to placebo plus chemotherapy in advanced gastric cancer patients.
Watch
EP. 4: Sequencing Between Available Therapies
March 13th 2025Panelists discuss how the optimal sequencing between available therapies for advanced gastric cancer remains challenging but should be guided by patient-specific factors, prior treatment response, and molecular characteristics of the tumor.
Watch
EP. 5: RECAP: Final Thoughts on RATIONALE-305
March 13th 2025Panelists discuss how RATIONALE-305 represents a significant advancement in first-line treatment for advanced gastric cancer with tislelizumab demonstrating meaningful survival benefits while maintaining a tolerable safety profile that could potentially reshape standard clinical practice.
Watch
